Founded in 2017, Oxford Cannabinoid Technologies is a biopharmaceutical company focused on researching, developing, and licensing cannabinoid-based compounds and therapies. We bring together researchers and clinicians from academia with cannabinoid experts to advance our understanding of the medical properties of cannabis and develop new therapies.

OCT was established by UK investment firm Kingsley Capital Partners, in conjunction with other investors. Through our close partnership with the University of Oxford, we have access to world leading scientists, expertise, and facilities.

By employing 21st century science to provide more evidence for the effects of cannabinoids in a number of diseases, it is our vision to become a global leader in cannabinoid-based medication, improving the quality of life for millions of patients.

Oxford Cannabinoid Technologies is the only pharmaceutical company partnered with a top-tier research institution that will focus exclusively on the discovery and development of novel cannabinoid-based therapies.

With these resources, it is our vision to become a global leader in cannabinoid-based therapies improving the quality of life for millions of patients.